Pfizer

Stories 201 - 204 | << Prev 

Big Pharma Faces Big Plunge
Big Pharma Faces Big Plunge

Big Pharma Faces Big Plunge

Profits will drop as patents expire, and chemical-based therapies are eclipsed by biotech

(Newser) - Patent protections on some of the pharmaceutical industry's best-selling drugs, like Lipitor, Plavix and Singulair, are due to expire in the next several years, and drug manufacturers have little in the pipeline to replace them. The drug companies will lose billions—as much as half their combined revenue—to generic...

Battle Brews in Pharma's Market
Battle Brews in Pharma's Market

Battle Brews in Pharma's Market

Pfizer launches attack on generic drug that threatens Lipitor's dominance

(Newser) - Pfizer is trying to stave off its own heart attack now that its flagship cholesterol-lowering drug Lipitor faces stiff competition from a cheaper generic. Lipitor is still patent-protected, but a very similar drug called Zocor isn't, and since a generic version called simvastatin hit the market, many doctors and insurers...

Pfizer Down 77% on Loss of Exubera
Pfizer Down 77% on Loss
of Exubera

Pfizer Down 77% on Loss of Exubera

Third-quarter earnings take hit on failure of inhaled-insulin drug

(Newser) - The world's largest drug maker took a 77% hit in third-quarter net income after dropping Exubera, its inhaled insulin product. Competition from generic drugs also pulled down sales, Pfizer announced this morning, as the company lowered its 2007 net-income forecast.

Nigeria Sues Pfizer Over Deadly Tests

$7B suit claims drug giant carried out disastrous trials on children

(Newser) - Nigeria is suing pharma giant Pfizer for $7 billion, claiming the company carried out improper trials on children. 200 children in the state of Kano died, and others developed deformities, after Pfizer tested Trovan, an experimental antibiotic, during a 1996 meningitis outbreak. Nigeria claims the tests were unauthorized, but Pfizer...

Stories 201 - 204 | << Prev 
Most Read on Newser